Illumina Inc. (ILMN) shares experienced a significant 5.06% plunge in the 24-hour period leading up to the close of the pre-market trading session on Tuesday, February 4th. This sharp decline in the biotechnology company's stock price appears to be driven by escalating trade tensions between the United States and China, as well as China's decision to add Illumina to its "unreliable entity list".
Amid the ongoing trade dispute between the two economic superpowers, China imposed retaliatory tariffs on various U.S. goods, including a 15% levy on coal and liquefied natural gas exports, and a 10% tariff on crude oil and agricultural machinery. This move came swiftly after President Donald Trump implemented a 10% tariff on all Chinese exports to the U.S., citing concerns over illegal drug trafficking.
In a separate but related development, China's Commerce Ministry announced that it had placed Illumina, along with apparel company PVH Corp., on its "unreliable entity list". This decision was attributed to allegations that these companies had taken "discriminatory measures against Chinese enterprises" and "damaged" the legitimate rights and interests of Chinese companies. The inclusion on this list could potentially lead to sanctions or other punitive measures against Illumina within the Chinese market.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。